Research programme: herpes simplex virus vaccine - AlphaVax

Drug Profile

Research programme: herpes simplex virus vaccine - AlphaVax

Alternative Names: HSV alphavaccine - AlphaVax; HSV vaccine - AlphaVax

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AlphaVax
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Herpes simplex virus infections

Most Recent Events

  • 08 Dec 2017 HSV vaccine is still in preclinical development for Herpes-simplex-virus-infections Herpes-simplex-virus-infections in USA (AlphaVax pipeline, December 2017)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Herpes-simplex-virus-infections in USA (Parenteral)
  • 10 Sep 2015 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top